08Jun 2024
Study Shows Apatinib Plus Chemotherapy Enhances Treatment Efficacy in Recurrent Platinum-Resistant Ovarian Cancer

Study Shows Apatinib Plus Chemotherapy Enhances Treatment Efficacy in Recurrent Platinum-Resistant Ovarian Cancer

A recent study assessed the effectiveness and safety of combining the angiogenesis inhibitor apatinib with chemotherapy in patients with recurrent platinum-resistant ovarian cancer (RPR-OC). Researchers analyzed data from 67 RPR-OC patients who either received apatinib plus chemotherapy or chemotherapy alone. The results suggested that the combination therapy group exhibited higher objective response rates and disease control rates than the chemotherapy-alone group. Moreover, patients in the combination therapy group showed prolonged progression-free survival (PFS) and overall survival (OS) rates. These findings suggest that apatinib plus chemotherapy may improve treatment outcomes for RPR-OC patients with manageable safety.

  • #oncology

Like

Save

Share